Blockmir Technology to Selectively Up Regulate Therapeutic Targets and Neutralise Disease-Associated microRNA Activity

Case ID: 068

Web Published: 6/15/2015

Overview

Mirrx Therapeutics A/S is commercializing innovative ”Blockmir” oligonucleotide technology, a proprietary therapeutic paradigm with potential to (i) enhance the protein expression of previously undruggable targets, and (ii) neutralise pathological microRNA expression via selective blockade of microRNA-based gene regulation.

Blockmir
Blockmir drugs are differentiated, and expected to be superior to other technologies designed to enhance protein expression or modulate microRNA activity, benefiting from ease of design, promotion of endogenous, physiological and tissue-specific protein expression, attractive pharmacokinetics and formulation. Having generated exciting proof of principle data, Mirrx is now interested to enter into strategic collaborations to design, develop and commercialise Blockmir therapeutic drugs.

Buy Technology

Patent Information:

Title	App Type	Country	Serial No.	Patent No.	File Date	Issued Date	Expire Date	Patent Status
Blockmir Technology to Selectively Up Regulate Therapeutic Targets and Neutralise Disease-Associated microRNA Activity	Plant Breeders Rights	*United States	0wr08f820o22223
Blockmir Technology to Selectively Up Regulate Therapeutic Targets and Neutralise Disease-Associated microRNA Activit	Utility	*United States		9661651456				Patented Case